生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Lamotrigine belongs to the second generation of antiepileptic drugs (AEDs)[3]. Co-application of lamotrigine (1 ~ 300 µM) resulted in a concentration-dependent reduction in peak amplitude of currents induced by 3 µM of 5-HT for an IC50 value of 28.2 ± 3.6 µM with a Hill coefficient of 1.2 ± 0.1[4]. Moreover, intrathecally administered lamotrigine could prevent the activation of the glutamate receptors involved in pain transmission and central sensitization, such as AMPA, NMDA, and metabotropic receptors[5]. Studies showed lamotrigine could ameliorate executive dysfunction and brain inflammatory response in the mouse model of AD[6]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00206778 | Mixed Mania Bipolar Disorder | Phase 2 | Completed | - | United States, New York ... 展开 >> Beth Israel Medical Center New York, New York, United States, 10003 收起 << |
NCT00104416 | Epilepsy, Tonic-Clonic | Phase 3 | Completed | - | - |
NCT02283801 | Epilepsy | Phase 1 | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
3.90mL 0.78mL 0.39mL |
19.52mL 3.90mL 1.95mL |
39.05mL 7.81mL 3.90mL |
参考文献 |
---|